LifeSci Communications
LifeSci Communications is dedicated to transforming science into compelling stories, helping clients realize their mission through a fusion of scientific and communication expertise. They focus on scientific and medical communications, corporate communications, integrated marketing, creative solutions, and patient recruitment for clinical trials.
Industries
Nr. of Employees
medium (51-250)
LifeSci Communications
Products
Clinical Trial Campaigns
Recruitment strategy, patient advocacy, and digital targeting services for clinical trials.
Branding & Creative
Corporate and product branding, website development, creative campaigns, and visual identity services.
Public Relations & Media
Media strategy, investor visibility, executive communications, outreach, and content development services.
Product Communications
Launch planning, value proposition development, stakeholder messaging, and internal communications services.
Digital Engagement
Social media strategy, digital media, paid campaigns, and analytics services.
Scientific & Medical Communications
Mechanism-of-action illustrations, scientific platforms, and scientific visualization services.
Clinical Trial Campaigns
Recruitment strategy, patient advocacy, and digital targeting services for clinical trials.
Branding & Creative
Corporate and product branding, website development, creative campaigns, and visual identity services.
Public Relations & Media
Media strategy, investor visibility, executive communications, outreach, and content development services.
Product Communications
Launch planning, value proposition development, stakeholder messaging, and internal communications services.
Digital Engagement
Social media strategy, digital media, paid campaigns, and analytics services.
Scientific & Medical Communications
Mechanism-of-action illustrations, scientific platforms, and scientific visualization services.
Services
Development and execution of corporate messaging for external stakeholders including press and investors.
Strategic multi-channel communications programs aligning scientific content with marketing and commercial objectives.
Design and production of creative assets and campaign materials tailored to scientific and healthcare audiences.
Medical writing and scientific communications that translate complex data into clear materials for clinicians, regulators and researchers.
Communications-driven patient recruitment strategies and outreach to support enrollment in clinical studies.
Curation and delivery of conference panels and thought-leadership sessions to convene experts and shape discussions at industry events.
Development and execution of corporate messaging for external stakeholders including press and investors.
Strategic multi-channel communications programs aligning scientific content with marketing and commercial objectives.
Design and production of creative assets and campaign materials tailored to scientific and healthcare audiences.
Medical writing and scientific communications that translate complex data into clear materials for clinicians, regulators and researchers.
Communications-driven patient recruitment strategies and outreach to support enrollment in clinical studies.
Curation and delivery of conference panels and thought-leadership sessions to convene experts and shape discussions at industry events.
Expertise Areas
- Scientific and medical communications
- Patient recruitment communications for clinical trials
- Integrated marketing and brand strategy for life sciences
- Corporate and stakeholder communications
Key Technologies
- Web analytics and tracking
- Digital content production (blogs, podcasts, embedded media)
- Social media and digital channels
- Content management systems
News & Updates
Boehringer Ingelheim has invested in Cue to develop B-cell depletion therapies for autoimmune diseases, paying Cue $12 million to advance this approach.
Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.
Boehringer Ingelheim has invested in Cue to develop B-cell depletion therapies for autoimmune diseases, paying Cue $12 million to advance this approach.
Florida-based Syncromune presented the first-ever clinical data from SYNC-T, a personalized platform therapy that uses a drug-device combination, in metastatic castration-resistant prostate cancer.